BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19102416)

  • 1. Clinicopathological significance of urokinase-type plasminogen activator genotypes in gastric cancer.
    Wu CY; Wu MS; Chen YJ; Chen HP; Chen CJ; Chang CS; Lin JT
    Hepatogastroenterology; 2008; 55(86-87):1890-4. PubMed ID: 19102416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SERPINE1 intron polymorphisms affecting gene expression are associated with diffuse-type gastric cancer susceptibility.
    Ju H; Lim B; Kim M; Noh SM; Kim WH; Ihm C; Choi BY; Kim YS; Kang C
    Cancer; 2010 Sep; 116(18):4248-55. PubMed ID: 20549826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A C/T polymorphism in the urokinase-type plasminogen activator gene in colorectal cancer.
    Przybylowska K; Smolarczyk K; Blasiak J; Kulig A; Romanowicz-Makowska H; Dziki A; Ulanska J; Pander B
    J Exp Clin Cancer Res; 2001 Dec; 20(4):569-72. PubMed ID: 11876553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of matrix metalloproteinase-9 protein polymorphisms with lymph node metastasis but not invasion of gastric cancer.
    Tang Y; Zhu J; Chen L; Chen L; Zhang S; Lin J
    Clin Cancer Res; 2008 May; 14(9):2870-7. PubMed ID: 18451255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of cyclooxygenase-2 and urokinase plasminogen activator in gastric carcinoma and the clinical significance thereof].
    Zhang FH; Zhou YN; Li GZ; Li Q; Lu B; Zhang ZY; Wu ZQ; Fan P; Hao TJ
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(46):3279-82. PubMed ID: 19159555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer.
    Wu CY; Wu MS; Chen YJ; Chen CJ; Chen HP; Shun CT; Chen GH; Huang SP; Lin JT
    Eur J Cancer; 2007 Mar; 43(4):799-808. PubMed ID: 17236757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma.
    Okusa Y; Ichikura T; Mochizuki H
    Cancer; 1999 Mar; 85(5):1033-8. PubMed ID: 10091785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlation between the expression of urokinase-type plasminogen activator, E-cadherin and malignancy in gastric cancer].
    Itoh H; Yonemura Y; Tsuchihara K; Kawamura T; Nojima N; Kaji M; Fushida S; Nishimura G; Fujimura T; Miwa K
    Gan To Kagaku Ryoho; 1995 Jun; 22 Suppl 2():124-9. PubMed ID: 7611774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer.
    Zlobec I; Minoo P; Baumhoer D; Baker K; Terracciano L; Jass JR; Lugli A
    Cancer; 2008 Feb; 112(3):495-502. PubMed ID: 18076013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of C-->T and T-->C polymorphisms of the urokinase-type plasminogen activator gene in children with type 1 diabetes mellitus and insulin resistance.
    Majsterek I; Przybylowska K; Mlynarski W; Drzewoski J; Blasiak J
    Clin Exp Med; 2005 Mar; 4(4):202-6. PubMed ID: 15750768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance in gene expression of matrix metalloproteinase-9, urokinase-type plasminogen activator and tissue inhibitor of metalloproteinase for metastases of gastric and/or colo-rectal cancer].
    Koumura H; Sugiyama Y; Kunieda K; Saji S
    Gan To Kagaku Ryoho; 1997 Jul; 24 Suppl 2():324-31. PubMed ID: 9263524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Kumano M; Miyake H; Muramaki M; Furukawa J; Takenaka A; Fujisawa M
    Urol Oncol; 2009; 27(2):180-6. PubMed ID: 18439850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression and significance of urokinase-type plasminogen activator in breast cancer].
    Xiao J; Zhang G; Xia W
    Zhonghua Zhong Liu Za Zhi; 1999 May; 21(3):196-8. PubMed ID: 11776834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms--a case-control study in an Omani population.
    Al-Moundhri MS; Al-Nabhani M; Burney IA; Al-Farsi AA; Al-Bahrani B
    Mol Carcinog; 2009 Dec; 48(12):1170-6. PubMed ID: 19676106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
    Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
    Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression.
    De Feo E; Persiani R; La Greca A; Amore R; Arzani D; Rausei S; D'Ugo D; Magistrelli P; van Duijn CM; Ricciardi G; Boccia S
    Mutat Res; 2009 Apr; 675(1-2):60-5. PubMed ID: 19386249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
    Lei H; Hemminki K; Johansson R; Altieri A; Enquist K; Henriksson R; Lenner P; Försti A
    Breast Cancer Res Treat; 2008 May; 109(1):165-75. PubMed ID: 17616807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer.
    Vidal O; Metges JP; Elizalde I; Valentíni M; Volant A; Molina R; Castells A; Pera M
    Br J Surg; 2009 Dec; 96(12):1443-51. PubMed ID: 19918848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.